AbbVie (NYSE:ABBV) Shares Down 2.2% on Analyst Downgrade

Shares of AbbVie Inc. (NYSE:ABBV) fell 2.2% during trading on Wednesday after Citigroup lowered their price target on the stock from $235.00 to $230.00. Citigroup currently has a neutral rating on the stock. AbbVie traded as low as $216.70 and last traded at $218.9880. 4,986,646 shares changed hands during mid-day trading, a decline of 31% from the average session volume of 7,220,492 shares. The stock had previously closed at $223.93.

ABBV has been the subject of several other research reports. Morgan Stanley increased their price objective on shares of AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Piper Sandler reiterated an “overweight” rating and set a $289.00 target price (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Bank of America upped their price objective on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $249.37.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie and Novartis announced multi‑billion dollar licensing deals in oncology and Alzheimer’s, which could expand AbbVie’s long‑term revenue runway and pipeline breadth. AbbVie and Novartis Announce Billion Dollar Licensing Deals for Oncology and Alzheimer’s Treatments
• Positive Sentiment: Coverage of a bispecific trial “win” and AbbVie’s increased R&D focus could materially improve the bull case if confirmed — upside to sentiment and valuation depends on readouts and development milestones. Does AbbVie’s Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?
• Positive Sentiment: Analyst support: Berenberg raised its price target to $275 citing Skyrizi and Rinvoq momentum, signaling confidence in underlying specialty‑drug growth. Berenberg Grows More Confident in AbbVie (ABBV) on Skyrizi and Rinvoq Momentum
• Positive Sentiment: CNBC guest recommended staying long AbbVie, reflecting some bulls’ view that dividend, pipeline and specialty momentum justify ownership. AbbVie, SLB, Amphenol, And More On CNBC’s ‘Final Trades’
• Positive Sentiment: Allergan Aesthetics posted new data (including TrenibotE and long‑term onabotulinumtoxinA results) that support the aesthetics franchise—helpful for non‑immunology revenue diversification. Allergan Aesthetics Unveils New Data Across Facial Injectables…
• Neutral Sentiment: Options flow has shown activity suggesting traders expect potential near‑term volatility or a directional move, but this is ambiguous on direction. Is the Options Market Predicting a Spike in AbbVie Stock?
• Neutral Sentiment: Small institutional activity: Belpointe Asset Management modestly increased its stake — a relatively minor vote of confidence. Belpointe Asset Management LLC Increases Stake in AbbVie Inc. $ABBV
• Negative Sentiment: U.S. Medicare named several AbbVie drugs for the next round of price‑negotiations — this raises medium‑term downside risk to pricing and revenue for affected products. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: Competitive risk: Corcept reported robust Phase III ovarian‑cancer data that could challenge treatments from Merck and AbbVie in that indication, implying potential market share pressure. Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III…
• Negative Sentiment: Near‑term earnings risk: Zacks notes AbbVie lacks the setup for a likely earnings beat next week; Citi trimmed its price target to $230 and put a neutral rating — both can weigh on share sentiment ahead of results. AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth Benzinga

Institutional Trading of AbbVie

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ABBV. Brighton Jones LLC raised its position in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the period. Invesco LLC grew its position in AbbVie by 59.0% during the second quarter. Invesco LLC now owns 1,631 shares of the company’s stock worth $303,000 after buying an additional 605 shares in the last quarter. Baron Silver Stevens Financial Advisors LLC increased its position in shares of AbbVie by 8.3% in the second quarter. Baron Silver Stevens Financial Advisors LLC now owns 2,393 shares of the company’s stock worth $444,000 after purchasing an additional 183 shares during the period. Finally, Elser Financial Planning Inc acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $502,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Price Performance

The business’s fifty day moving average price is $225.14 and its 200 day moving average price is $218.00. The stock has a market cap of $387.04 billion, a P/E ratio of 165.90, a PEG ratio of 0.91 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s dividend payout ratio is presently 524.24%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.